Tetraphase hauls in $45M C round to back antibiotic work

Watertown, MA-based Tetraphase Pharmaceuticals has hauled in a $45 million C round--a hefty chunk of cash that will open a development runway stretching out up to two-and-a-half years. Over that time, CEO Guy Macdonald tells FierceBiotech, the company will put its technology for developing a better breed of tetracycline antibiotics to the clinical development test, taking a lead program--TP-434--through Phase II and ushering two more into the clinic. By the end of this stretch, the biotech...